Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Pembrolizumab Monotherapy in Unresectable Cutaneous Squamous Cell Carcinoma
2016-002076-28Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Objective response rate at 15 weeks by RECIST v1.1. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2016-002076-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002076-28.